Lidocaine Infusion for Pain After Herniotomy
Unknown statusNot applicableNCT03673163
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study seeks to investigate lidocaine infusion to reduce occurrence of chronic postoperative pain at 3-month after inguinal herniotomy
Study details
- Official title
- Lidocaine Infusion for Pain After Herniotomy (LIPAH), A Randomized Placebo-controlled Trial (LIPAH Trial)
- Conditions
- Interventions
- Drug: Lidocaine
- Drug: Control
- Sponsor
- Guangzhou First People's Hospital
- Start date
- 2018-11-06
- Primary completion
- 2019-06-30
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients scheduled to undergo unilateral inguino herniotomy Exclusion Criteria: * (1)ASA classification status III or above * (2)Body weight\<35kg * (3)Liver cirrhosis * (4)A history of previous herniotomy * (5)Pregnancy * (6)Severe arrhythmia * (7)Congestive heart failure * (8)Opioid or steroid use 6 months before surgery * (9)Allergy to lidocaine * (10)Chronic pain syndrome (any type) * (11)Emergency surgery * (12)Incapacity to give an informed consent, Visual dysfunction or severe mental disorders
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03673163